Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous PRG and BMMSCs for Diabetic Foot Ulcer
NCT03248466Phase 1Unknown
- Sponsor
- Army Medical University
- Start
- Aug 2017
- Primary completion
- Jan 2020
- Modality
- Hydrogel Systems, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous platelet rich gel and autologous bone-marrow mesenchymal stem cells in diabetic foot ulcer (DFU) (3 arms), sponsored by Army Medical University. Primary endpoints: Amputation rate at 6 months and Hospital stay at 6 months. Status: unknown.
02
Drugs
autologous platelet rich gelautologous bone-marrow mesenchymal stem cells
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03248466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248466.